Coburn Lecture Will Cover Fibroblast Growth Factor-23 Risks

Full access

Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality, which will be the subject of the Jack W. Coburn, MD, Endowed Lectureship, on Thursday, Nov. 7.

Sharon M. Moe, MD

Sharon M. Moe, MD, will speak on “FGF23 and Risks of Cardiovascular and Noncardiovascular Diseases.” Dr. Moe is director of the division of nephrology and Stuart A. Kleit Professor of Medicine at the Indiana University School of Medicine. She has been a faculty member at Indiana University since 1992 and

Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality, which will be the subject of the Jack W. Coburn, MD, Endowed Lectureship, on Thursday, Nov. 7.

d795194e55

Sharon M. Moe, MD

Citation: Kidney News 11, 10/11

Sharon M. Moe, MD, will speak on “FGF23 and Risks of Cardiovascular and Noncardiovascular Diseases.” Dr. Moe is director of the division of nephrology and Stuart A. Kleit Professor of Medicine at the Indiana University School of Medicine. She has been a faculty member at Indiana University since 1992 and was recently named distinguished professor. She has also served as the associate dean for research support in the school of medicine and vice chair for research in the department of medicine.

Dr. Moe’s research is translational and involves the study of all aspects of chronic kidney disease–mineral bone disorder. She is the principal investigator for several basic and clinical research studies in the field, including studies on vascular calcification, mineral metabolism, and bone metabolism in kidney disease. She has studied the pathogenesis of vascular calcification in animal models and human studies, evaluated the role of abnormal bone in the pathogenesis of vascular calcification, examined treatments to reduce fractures, and examined the role of nutrition.

She has also been involved in the design and conduct of clinical trials for multiple drugs to treat hyperphosphatemia and secondary hyperparathyroidism.

Her research has been funded by the National Institutes of Health and Department of Veterans Affairs for more than 20 years. She has authored over 200 scientific manuscripts, teaching manuscripts, and textbook chapters.

Dr. Moe served on the National Kidney Foundation’s bone and mineral metabolism clinical practice guidelines committee in 2003, co-chaired the international Kidney Disease: Improving Global Outcomes mineral and bone guidelines committee in 2009, and was a member of the 2017 update committee.

Dr. Moe served as president of the American Society of Nephrology in 2013–2014 and has served ASN in many other capacities as well.

She has served on the executive committee of the Kidney Disease Outcomes Quality Initiative, on the American Heart Association kidney council, and as councilor to the International Society of Nephrology. Her service on editorial boards includes JASN, American Journal of Kidney Diseases, and American Journal of Nephrology.

Key honors she has received include election to the American Society for Clinical Research and the National Kidney Foundation Garabed Eknoyan Award for exceptional contributions.

She attended the University of Illinois College of Medicine at Chicago, was an intern and resident at Loyola University Medical Center in Maywood, Ill., and completed a nephrology fellowship at the University of Chicago.

Save